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Objective: To describe self-reported menopausal symptom priorities and their 
association with demographics and other symptoms among participants in an intervention trial 
for vasomotor symptoms (VMS). 
Methods: Cross-sectional study embedded in the MsFLASH 02 trial, a three by two 
factorial design of yoga vs. exercise vs. usual activity and omega-3-fatty acid vs. placebo. At 
baseline, women (n=354) completed hot flash diaries, a card sort task to prioritize symptoms 
they would most like to alleviate, and standardized questionnaires.  
Results: The most common symptom priorities were: VMS (n=322), sleep (n=191), 
concentration (n=140), and fatigue (n=116). In multivariate models, (1) women who chose VMS 
as their top priority symptom (n=210) reported significantly greater VMS severity (p=0.004) and 
never smoking (p=0.012) and (2) women who chose sleep as their top priority symptom 
(n=100), were more educated (p<0.001) and had worse sleep quality (p<0.001). ROC curves 
identified sleep scale scores that were highly predictive of ranking sleep as a top priority 
symptom.  
Conclusions: Among women entering an intervention trial for VMS and with relatively low 
prevalence of depression and anxiety, VMS was the priority symptom for treatment. A card sort 
may be a valid tool for quickly assessing symptom priorities in clinical practice and research. 
   




 Most women experience multiple, concurrent menopausal symptoms at midlife.1-5 
Although vasomotor symptoms (VMS) have been the focus of most intervention studies,6, 7 they 
do not occur in isolation. VMS frequently co-occur with disturbed sleep and mood, fatigue, 
trouble remembering or concentrating, and/or sexual difficulties.1-3, 8-10 These co-occurring 
symptoms are typically not assessed or are considered secondary outcomes, with few trials 
specifically targeting more than one symptom.6, 7, 11, 12 Research shows that symptoms act 
synergistically and that the impact of co-occurring symptoms on an individual is multiplicative 
rather than additive.9, 13 Thus, addressing multiple co-occurring symptoms is vital to improving 
midlife women’s quality of life.  
 Little is known about how women view the relative importance of their menopausal 
symptoms.14 During clinic visits, symptoms are often discussed with providers but not 
necessarily ranked by relative importance which may result in under-treatment of the symptom 
women would most like to alleviate. Investigating the relative importance of menopausal 
symptoms to each woman would provide useful information for understanding how to design 
research trials to alleviate co-occurring symptoms and prioritize therapeutic discussions and 
treatment recommendations by providers in clinical practice. Furthermore, understanding 
demographic correlates of symptom priorities would be informative for identifying at risk patients 
in clinical practice and designing research sampling plans. For example, it is likely that symptom 
priorities vary by race given that higher rates of VMS15 and disturbed sleep16-18 are reported by 
African American women compared to white women. In addition, understanding whether 
symptom priorities are correlated with ratings and scores on other symptom measures, such as 
diaries or standardized scales, is important for both research and practice. Symptoms that 
exceed cutoff scores (i.e. those that are more severe) are likely to be more salient, but when 
several symptoms exceed cutoff scores, women may differ on how they prioritize each 
symptom’s relative importance.  
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The study objective was to describe menopausal symptom priorities among women 
participating in a behavioral intervention trial for VMS treatment and their association with 
demographic characteristics and other symptom measures. We anticipated that distinct patterns 
of symptom priorities would emerge and that these would be associated with demographic 
correlates and cutoff scores.   
METHODS 
Design 
This cross-sectional study was embedded within the second trial conducted by the 
United States research network, MsFLASH (Menopause Strategies Finding Lasting Answers to 
Symptoms and Health). Details of the MsFLASH protocol and research study are published 
elsewhere.19, 20 Briefly, the trial was a three by two factorial design comparing yoga and exercise 
vs. usual activity and omega-3 supplements vs. placebo for the treatment of VMS (primary 
outcome) and menopausal symptoms of disturbed sleep and mood, pain, sexual function, and 
quality of life (secondary outcomes). All data reported here are from the baseline data collection. 
Procedures were approved by the institutional review boards at each clinical site (Indianapolis, 
Oakland, and Seattle) and the Data Coordinating Center in Seattle. All research participants 
provided written, informed consent and authorization to use protected health information.  
Sample 
Participants were recruited between February 2011 and January 2012. Mass mailings 
were sent to women aged 40-62 years using purchased lists and health-plan enrollment files. 
Women were screened via telephone for eligibility and then via a two-week VMS diary and 
questionnaire. Potentially eligible women completed a third week of diaries. Eligible women 
were 40-62 years old; in the menopausal transition or early postmenopause or had had a 
hysterectomy with FSH >20 mIU/mL and estradiol <50 pg/mL; and in generally good health. The 
VMS eligibility criteria were: >14 hot flashes/night sweats per week recorded on daily VMS 
diaries for 3 weeks; VMS rated as bothersome or severe on 4 or more occasions per week; and 
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the VMS frequency in week 3 did not decrease > 50% from the average weekly levels in weeks 
1 and 2. Exclusion criteria included: BMI > 37; use of hormonal contraceptives or hormones in 
the past month; use of prescription or over-the-counter treatments for VMS in the past month; 
unstable medical conditions; current user of one of the study interventions or a related activity 
(i.e., yoga, tai chi, qi gong, meditation, regular exercise, omega-3 fatty acid supplements, 
frequent consumption of fish); contraindications to exercise (e.g., physical limitations), yoga, or 
omega-3 (e.g., allergy to soy or fish); or a major depressive episode in the past 3 months.  
Procedures 
Study screening was done via telephone followed by two weeks of at-home daily VMS 
diaries. Women whose diaries indicated they met VMS inclusion criteria completed two baseline 
clinic visits scheduled one week apart before being randomized to the interventions. All 
measures used for this study were collected during the trial’s baseline data collection period.   
Measures 
Symptom priorities were assessed using a card sort methodology. Women were given a 
set of 12 symptom cards: hot flashes or night sweats; disturbed sleep; feeling tired or worn out 
(fatigue); trouble remembering or concentrating (concentration); loss of interest in sex; vaginal 
dryness or pain with sexual intercourse; uncontrollable loss of urine; mood swings; feeling 
irritable; aches and pains; headaches; or heart palpitations. Research staff instructed women to 
select three cards representing the top three symptoms they would “most like to get rid of or be 
free of.” Once the three cards were selected from the deck, research staff then asked women to 
rank order the cards from one to three, with one representing the top symptom, two the second 
symptom, and three the third symptom they would most like to alleviate. Responses were 
recorded onto a paper form and data entered by study staff.  
VMS frequency, severity and bother were recorded twice daily for three weeks; two 
weeks prior to the first baseline visit and during the one week between the two baseline visits. 
Women were instructed to use the diaries in the morning to write down the number, severity 
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rating, and bother rating of their nighttime VMS and similarly use the diaries at bedtime to record 
daytime VMS. Severity was rated as mild, moderate, or severe. Bother was rated as not at all, a 
little, moderate, or a lot. Ratings were used to calculate daily mean frequency, severity, and 
bother.  
Hot flash interference was assessed with the 10-item Hot Flash Related Daily 
Interference Scale (HFRDIS).21 Participants rated the degree to which hot flashes interfered with 
each item during the previous week using a 0 (do not interfere) to 10 (completely interfere) 
scale. This uni-dimensional scale is best represented by an overall mean score (sum of 
items/10) with higher scores representing higher levels of daily interference.22  
Sleep was assessed using two scales; the 18-item Pittsburgh Sleep Quality Index 
(PSQI)23, 24 and the 7-item Insomnia Severity Index (ISI).25, 26 Both were used since the PSQI 
focuses broadly on overall sleep quality and the ISI is more specific to insomnia symptoms. 
PSQI global scores above 5 indicate poor sleep quality and above 8 indicate very poor sleep 
quality and daytime fatigue.27 ISI insomnia severity is interpreted using total scores as none (0–
7), subthreshold (8–14), moderate (15–21), and severe (22–28).25, 26  
Data Analysis 
Analyses were conducted using SAS Version 9.3. Sample demographics were analyzed 
using descriptive statistics (n=355). Symptoms were ranked by number of top priority symptoms 
and the total number of first, second, and third priority symptoms. Frequencies and a Venn 
diagram were used to evaluate how symptoms were prioritized and how the overlap among 
symptoms was distributed within the sample. Participants were categorized by top priority 
symptoms. VMS and disturbed sleep were the most highly prioritized symptoms (VMS 210 first 
+ 78 second place votes; disturbed sleep 48 first + 100 second place votes).  
The sample was divided based on symptom priorities. We performed several analyses 
between (1) women who did and did not pick VMS as their top priority symptom and (2) women 
who did and did not pick disturbed sleep as their top priority symptom. Univariate and then 
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multivariate comparisons and receiver operating characteristic (ROC) curve analyses were 
performed as outlined below.  
Demographics, hot flash diary, and hot flash interference scores were compared using 
chi-square and t-tests between women who rated VMS as their first priority symptom to alleviate 
(n=210) and women who did not (n=144). We fit a logistic regression model estimating the 
probability of picking VMS symptoms as the first priority to alleviate as a function of VMS 
frequency, severity, and interference, adjusted for those baseline characteristics with a p value 
less than 0.2 from the univariate tests. VMS bother was not included in the model because of its 
high correlation with VMS severity. 
Similarly, we compared participant characteristics, PSQI, and ISI scores using chi-
square and t-tests between women who rated disturbed sleep as their first priority symptom to 
alleviate (n=48) and those who did not (n=296). We fit two logistic regression models – one as a 
function of PSQI scores and one as a function of ISI scores – both controlling for baseline 
characteristics with p values less than 0.2 from univariate tests.  
We plotted ROC curves and calculated the area under the ROC curves (AUC) from 
three unadjusted logistic regression models – one estimating the probability of choosing VMS as 
the priority symptom as a function of HFRDIS, and two models estimating the probability of 
choosing disturbed sleep as the priority symptom as a function of PSQI and ISI, respectively. If 
AUC > 0.7, indicating that the measurement had at least a fair level of efficacy in predicting 
participant choice, then we applied the ROC curve to select an optimal cut point in the scale for 
predicting a participant’s choice, treating sensitivity and specificity as equally important. 
RESULTS 
The sample included 354 women with card sort data. Most of the women were in their 
50’s (82%), white (64%) or African-American (26%), college graduates (62%) and married or 
partnered (66%). The majority had never smoked (65%) and were non-drinkers (38%) or 
reported drinking 1-7 alcoholic beverages per week (44%). BMI varied: 34% had a BMI < 25, 
Symptom Priorities 9 
 
 
41% had a BMI from 25-30, and 25% had a BMI > 30. Most (82%) were postmenopausal, and 
reported fair/good (37%) or very good (45%) health.  
Table 1 shows the total number of first-, second-, and third-ranked symptom priorities.  
The top 4 symptoms women most wanted to alleviate were hot flashes (n=322), disturbed sleep 
(n=191), trouble remembering or concentrating (n=140), and fatigue (feeling tired/worn out) 
(n=116).  VMS was the most highly prioritized symptom yet only 59% (n=210) of our study 
sample rated VMS as the top symptom they would most like to eliminate whereas 41% (n=144) 
picked another symptom. Disturbed sleep was the second most highly prioritized: 48 women 
picked disturbed sleep as the symptom they would most like to alleviate versus 296 who picked 
another symptom.  
Figure 1 shows co-occurrence among the top four symptoms. All but 2 participants 
selected at least 1 of the top 4 symptoms, thus the sample size for this figure is n=353. The 
most common co-occurrence was to select both VMS and disturbed sleep (n=96, 27% of the 
total sample) as two of the three priority symptoms to alleviate. In contrast, only 1 person picked 
disturbed sleep but not one of the other most highly prioritized symptoms.  
VMS as the Top Symptom Priority 
Table 2 shows unadjusted differences between women who selected VMS and those 
that did not. Compared to women who picked symptoms other than VMS as their top symptom 
to alleviate (n=145), women who picked VMS (n=210) were significantly more likely to be 
African-American (p=0.02), had significantly greater VMS frequency (p=0.019), severity 
(p=.005), bother (p<0.001), and tended to report greater VMS interference (p=0.052) (Table 2). 
Table 3 shows results of an adjusted logistic regression model identifying factors 
associated with selecting VMS as the top priority symptom to alleviate. Those who picked VMS 
reported greater VMS severity (OR 2.55, p=0.004) and were more likely to have never smoked 
(OR 1.90, p=0.012) after adjusting for the other variables. The AUC based on HFRDIS score 
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was 0.56 (n=328, 95% CI 0.50, 0.63), indicating a level of predictive accuracy that was no better 
than chance. 
Disturbed Sleep as Top Symptom Priority 
Table 2 shows unadjusted differences between women who selected disturbed sleep as 
their top priority symptom to alleviate and those that did not. Compared to women who picked 
symptoms other than sleep as their top symptom to alleviate (n=306), women who picked 
disturbed sleep as their top symptom (n=48) were significantly more likely to have Insomnia 
Severity Index scores > 15 (p<0.001) and Pittsburgh Sleep Quality Index scores > 8 (p<0.001). 
They also tended to have more education (p=0.044).  
Table 4 shows the results of adjusted logistic regression models predicting disturbed 
sleep as a top priority symptom. Both ISI (OR 1.22, P<0.001) and PSQI (OR 1.26, P<0.001) 
remained significant after adjusting for education, marital status, and smoking and drinking 
habits. Education also remained significant in both models and had similar effect sizes in each 
(OR=1.54 for PSQI and 1.50 for ISI).  
The AUC was 0.76 for ISI (N=350, 95% CI 0.70, 0.83) and 0.71 for PSQI (N=344, 95% 
CI 0.64, 0.78), indicating that both provided a fair level of accuracy for predicting whether or not 
a participant would pick disturbed sleep as most bothersome.  
If sensitivity and specificity were treated as equally important, then a PSQI score of 9 
was optimal to indicate a participant picked disturbed sleep as a top priority symptom to 
alleviate (sensitivity 66.7, specificity 63.9). This cutoff had a Youden’s index of 0.31 and would 
correctly classify 32 out of 48 women who picked sleep as most bothersome, and 189 out of 
296 who picked other symptoms as most bothersome. Similarly, an ISI score of 11 was optimal 
(sensitivity 89.6, specificity 44.7). This cutoff had the highest Youden’s index, 0.34 and would 
correctly classify 43 of the 48 women who picked sleep as most bothersome, but would only 
correctly classify 135 of the 302 women who picked other symptoms as most bothersome.  
DISCUSSION 
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 There were three principal findings from this study. First, VMS and disturbed sleep, 
followed by feeling tired (fatigue) and trouble remembering or concentrating, were overall the 
most highly prioritized symptoms that women presenting for a VMS treatment trial wanted to 
alleviate. Only slightly more than half of women enrolled in a trial for VMS treatment chose VMS 
as the top symptom they would most like to eliminate. Second, race/ethnicity and VMS severity 
but not HFRDIS scores were associated with women’s ranking of VMS as their top priority 
symptom to alleviate. Third, educational level and ISI and PSQI scores were associated with 
ranking disturbed sleep as a top priority symptom to alleviate.  
 Strengths and weaknesses of this study include the following. This was a large and 
relatively diverse sample from a multi-site study. Data were carefully annotated using daily 
diaries, the card sort and questionnaires that were administered during a clinic visit. VMS are 
the most common symptom associated with the menopausal transition associated with 
decreased health related quality of life and we focused on those with 2 or more bothersome 
VMS per day. The sample was limited to women who participated in a treatment trial for VMS 
and therefore results may not be generalizable to midlife women who are already receiving VMS 
treatment or who choose not to seek VMS treatment. However, it is important to note that even 
though these women were participating in a VMS treatment study, for 41% of them, VMS was 
not their priority symptom. In addition, women using selective serotonin reuptake inhibitors for 
VMS were excluded which may have disproportionately eliminated women with mood problems, 
an important menopausal symptom documented in other studies.2 This may at least partially 
account for the low ranking of mood and irritability in the card sort. The great majority of mid-life 
women experience frequent and bothersome VMS during the menopausal transition, and 
understanding the priorities for symptom relief among this large population group has a high 
degree of clinical relevance. 
 The emergence of disturbed sleep as a top priority symptom among this sample of 
women seeking treatment for VMS was not surprising. Numerous large population-based 
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studies have documented the co-occurrence of VMS and disturbed sleep.2, 5, 28 In addition, our 
study participants from this analysis were similar to participants in our other trials, nearly one-
third of whom had moderate to severe insomnia on the ISI and 40% of whom had poor 
subjective sleep quality on the PSQI.29 
 The emergence of low energy and problems with memory/concentration difficulties as 
top symptom priorities serves as an important reminder for assessing these symptoms in clinical 
practice and research. These symptoms were not assessed in our network trials except with 
these card sort data. Changes in concentration and memory were part of the symptom cluster 
documented in women participating in the Seattle Midlife Women’s Health Study.2 Similarly, 
verbal memory performance was related to the objectively recorded hot flash frequency in a 
study of 29 midlife women with moderate to severe hot flashes.30 Fatigue and memory/ 
concentration problems may be part of a cascade of symptoms resulting from disturbed sleep.  
Pain did not appear as a top priority symptom despite other studies showing it to be 
commonly experienced during menopause. In the Seattle Midlife Women’s Health study, mood 
and pain also emerged as important symptoms, 2 which differs from our results showing these 
were, respectively, the 8th and 10th most prioritized symptoms. Similarly, in the Penn Ovarian 
Aging study, aches and joint pain were among a handful of symptoms most commonly reported 
in the late transitional stage.10  
 When evaluating VMS as a top symptom to alleviate, VMS severity but not frequency or 
interference emerged as significant correlates. VMS frequency and severity were moderately 
correlated (r=0.36) and when the model was run without severity (not shown), frequency was 
significant (OR=1.13, p=0.02). However, severity with an odds ratio of 2.66 seems more salient.  
HFRDIS findings may reflect the importance of VMS severity in a woman’s life and/or limitations 
of the HFRDIS. In particular, the HFRDIS includes items related to VMS interference with sleep, 
concentration and sexuality,31 which may have resulted in it being a less than ideal measure for 
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differentiating women who selected VMS as the top symptom to alleviate and women who 
picked other symptoms such as disturbed sleep, concentration problems, or sexual concerns.    
 Importantly, associations between symptom priorities and diary VMS severity or 
standardized sleep measures indicate the card sort may be a valid and efficient method for 
quickly assessing symptom priorities in clinical practice or research. Because VMS are often co-
occurring with other menopausal symptoms, not all of which can be addressed at once or may 
not be fully controlled, the card sort could help clinicians identify women’s priorities for which 
symptoms to target first so treatment can be tailored accordingly. The card sort could be used 
as the first step of an assessment algorithm to guide more detailed symptom assessments 
tailored only to the subset of symptoms women would most like to alleviate.  This could result in 
greater efficiency and speed of symptom assessments in clinical practice and research, while 
retaining a focus on those symptoms women are most concerned about managing. Ultimately, 
the card sort assessment method with a tailored treatment approach could improve symptom 
management by reducing the burden and impact of these symptoms. 
Future research directions include repeating the card sort study in a more broadly 
selected sample of midlife women with bothersome menopause symptoms that may or may not 
include VMS to determine the replicability of our findings. Understanding the prioritization of 
symptoms in women not presenting for VMS trials might result in different findings. We also 
recommend studying the implementation of the card sort in clinical practice to assess feasibility 
in busy practice settings and potential impact on the clinical care of midlife women. In theory, a 
computerized version of the card sort could be directly linked to the electronic medical record to 
facilitate tracking and provide efficiency in clinical practice.   
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Figure 1: Co-occurrence of Menopausal Symptoms Prioritized as Those that Women 
Would Most Like to Alleviate 
 
Legend: Venn diagram depicting overlap among symptom priorities. Numbers are n (%). VMS 
are vasomotor symptoms. Sleep indicates disturbed sleep. Fatigue refers to feeling tired or worn 
out. Concentration refers to trouble remembering or concentrating. The four symptoms 
appeared most often as one of the top three symptoms women would most want to alleviate. 
There was 1 (0.28%) participant who did not pick any of the top four symptoms, thus this figure 
reflects n=353. The black center reflects the area of overlap not assessed since women rated 
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Table 1: Priorities for Menopausal Symptoms Women Would Most Like to Alleviate 
 Priority symptom  
  1st  %  2nd  %  3rd  %  Overall  %  
Hot Flashes/night sweats  210 59.2 75 21.1 37 10.4 322 90.7 
Disturbed sleep  48 13.5 100 28.2 43 12.1 191 53.8 
Remembering/concentrating  27 7.6 40 11.3 73 20.6 140 39.4 
Fatigue 27 7.6 40 11.3 49 13.8 116 32.7 
Loss of interest in sex  14 3.9 25 7.0 29 8.2 68 19.2 
Vaginal dryness or pain with 
sexual intercourse  9 2.5 17 4.8 39 11.0 65 18.3 
Uncontrollable loss of urine  5 1.4 14 3.9 10 2.8 29 8.2 
Mood swings  4 1.1 14 3.9 15 4.2 33 9.3 
Feeling irritable  4 1.1 12 3.4 22 6.2 38 10.7 
Aches and pains  3 0.9 8 2.3 19 5.4 30 8.5 
Headaches  2 0.6 5 1.4 4 1.1 11 3.1 
Heart palpitations  1 0.3 4 1.1 8 2.3 13 3.7 
 
 




Table 2: Demographic Differences between Women Based on First Priority Symptom Chosen to Alleviate 




Chose Other  
 N % N % p N % N % p 
Age group     0.390     0.482 
42-49 years 8 3.8 11 7.6  3 6.3 16 5.2  
50-54 years 101 48.1 61 42.4   19 39.6 143 46.7   
55-59 years 76 36.2 54 37.5   22 45.8 108 35.3   
60-62 years 25 11.9 18 12.5   4 8.3 39 12.7   
Ethnicity     0.019     0.654 
White 130 61.9 97 67.4  33 68.8 194 63.4  
African American 65 31.0 28 19.4   10 20.8 83 27.1   
Other / Unknown 15 7.1 19 13.2   5 10.4 29 9.5   
Education     0.273     0.044 
<= High school 
diploma or GED 16 7.6 5 3.5 
 
0 0.0 21 6.9 
 
Some post high 
school 62 29.5 50 34.7 
  
10 20.8 102 33.3 
  
College graduate 131 62.4 89 61.8   38 79.2 182 59.5   
Marital status     0.544     0.093 
Never married 18 8.6 16 11.1  9 18.8 25 8.2  
Divorced or 
separated 40 19.0 36 25 
  
10 20.8 66 21.6 
  
Widowed 4 1.9 3 2.1   1 2.1 6 2   
Married/Partnered 147 70.0 88 61.1   27 56.3 208 68   
Smoking     0.097     0.079 
Never 147 70.0 84 58.3  30 62.5 201 65.7  
Past 43 20.5 46 31.9   16 33.3 73 23.9   
Current 19 9.0 13 9   1 2.1 31 10.1   
Alcoholic 
drinks/week      
0.489 
    
0.106 
0 81 38.6 55 38.2  16 33.3 120 39.2  
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1 to <7 95 45.2 61 42.4   18 37.5 138 45.1   
7+ 32 15.2 28 19.4   14 29.2 46 15   
Body Mass Index     0.990     0.535 
< 25 73 34.8 49 34  14 29.2 108 35.3  
25 to <30 85 40.5 59 41   23 47.9 121 39.5   
>= 30 52 24.8 36 25   11 22.9 77 25.2   
Menopausal Status     0.443     0.486 
Postmenopausal 167 79.5 122 84.7  42 87.5 247 80.7  
Late transition 38 18.1 20 13.9   5 10.4 53 17.3   
Early transition 5 2.4 2 1.4   1 2.1 6 2   
Health Rating     0.314     0.600 
Excellent  39 18.6 19 13.2  8 16.7 50 16.3  
Very good 97 46.2 64 44.4   18 37.5 143 46.7   
Good / fair 73  61 42.4   22  112 36.6   
ISI          <0.001 
<= 15 165 78.6 95 66.0 0.008 21 43.8 239 78.1  
>15 (insomnia) 45 21.4 49 34.0  27 56.3 67 21.9  
PSQI          <0.001 
< 8 106 50.5 57 39.6 0.021 11 22.9 152 49.7  
>= 8 (poor sleep) 95 45.2 85 59.0   37 77.1 143 46.7   
 M SD M SD p M SD M SD p 
VMS diary frequency 4.7 2.5 4.0 2.5 0.005 3.8 1.9 4.5 2.6 0.079 
VMS diary severity 1.1 0.4 0.9 0.4 <0.001 0.8 0.4 1.0 0.4 0.005 
VMS diary bother 2.0 0.5 1.8 0.5 <0.001 1.8 0.5 2.0 0.5 0.004 
HFRDIS 34.3 21.9 29.7 21.1 0.052 30.8 18.3 32.7 22.2 0.594 
GED = general equivalency diploma; VMS = vasomotor symptoms; HFRDIS = Hot Flash Related Daily Interference Scale; ISI = 
Insomnia Severity Index; PSQI = Pittsburgh Sleep Quality Index 
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Table 3: Multivariate Logistic Regression Identifying Factors Associated with Women 
who Chose Hot Flashes as Priority Symptom to Alleviate 
   Odds Ratio (95% CI) P-value 
HFRDIS 1.00 (0.99, 1.02) 0.410 
VMS Frequency 1.07 (0.96, 1.19) 0.204 
VMS Severity 2.55 (1.35, 4.82) 0.004 
Ethnicity  White   (Reference) 0.136 
  African American  1.56 (0.88, 2.77)   
  Other / Unknown   0.68 (0.31, 1.48)   
Smoking Never   1.90 (0.82, 4.38) 0.012 
  Past  0.87 (0.35, 2.14)   
  Current   (Reference)   
HFRDIS = Hot Flash Related Daily Interference Scale; VMS = vasomotor symptoms 
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Table 4: Multivariate Logistic Regression Models Identifying Factors Associated with Women who Chose Disturbed Sleep 
as a Priority Symptom to Alleviate 
 
PSQI = Pittsburgh Sleep Quality Index; ISI = Insomnia Severity Index; CI = confidence interval 
  PSQI Model ISI Model 
Factor  Odds Ratio (95% CI) p Odds Ratio (95% CI) p 
Education  1.54 (1.19, 1.97) < .001 1.50 (1.16, 1.93) 0.002 
Marital  Never married 3.05 (1.15, 8.13) 0.167 3.70 (1.16, 1.94) 0.079 
Status Divorced or separated 1.40 (0.59, 3.33)  1.83 (0.75, 4.50)  
 Widowed 1.56 (0.16, 15.22)  1.59 (0.15, 17.28)  
 Married/Partnered (Reference)  (Reference)  
Smoking  Never (Reference) 0.341 (Reference) 0.356 
 Past 1.36 (0.62, 2.95)  1.35 (0.62, 2.93)  
  Current 0.30 (0.04, 2.40)  0.30 (0.04, 2.43)  
Alcoholic drinks/week None (Reference) 0.273 (Reference) 0.232 
 1 to < 7 1.06 (0.48, 2.35)  1.13 (0.49, 2.59)  
 7+ 2.02 (0.80, 5.13)  2.20 (0.84, 5.75)  
PSQI  1.26 (1.13, 1.40) <.001   
ISI    1.22 (1.13, 1.31) <.001 
